Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2326 to 2340 of 9010 results

  1. Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683]

    Awaiting development Reference number: GID-TA11053 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Focused Electrohydraulic Shockwaves for wound healing

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Clindamycin for treating bacterial vaginosis in females aged 12 and older [TSID 12127]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Rezafungin for preventing invasive fungal infections after an allogeneic blood and marrow transplant [TSID12165]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Syne Covid for predicting COVID-19 outcomes MT655

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  6. Respirasense

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  7. Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests

    In development Reference number: GID-DG10038 Expected publication date: TBC

    Diagnostics guidance
    In development

  8. Technologies for the detection of Hepatocellular Carcinoma

    Awaiting development Reference number: GID-HTG10175 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  9. Perfusion-induced systemic hyperthermia for the treatment of advanced lung cancer

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  10. Thromboaspiration for Intermediate risk Pulmonary Embolism

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  11. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor TSID 11812

    Topic prioritisation

    Health technology evaluations
    Topic prioritisation

  12. Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma PD [ID6527]

    Awaiting development Reference number: GID-TA11653 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]

    Awaiting development Reference number: GID-TA11489 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613]

    Awaiting development Reference number: GID-TA11469 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [TSID11810]

    Awaiting development Reference number: GID-TA11202 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development